The SELECT cardiovascular outcomes trial, published in the New England Journal of Medicine (2023), demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in people with established cardiovascular disease and overweight or obesity who did not have diabetes
Limitations of Available Evidence Research varies based on study design, dosing, and delivery method
Other Antidepressants : Bupropion may interact with other antidepressant medications, such as selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs), potentially increasing the risk of serotonin syndrome
The truth is that microdosing tends to be gentler on metabolism, which makes it easier to maintain muscle
If youre considering semaglutide injections as a treatment option, one of your primary concerns is likely the cost